Pfizer Inc. (NYSE:PFE) Shares Sold by Aspiriant LLC

Aspiriant LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 17.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,539 shares of the biopharmaceutical company’s stock after selling 6,473 shares during the period. Aspiriant LLC’s holdings in Pfizer were worth $837,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Royal Fund Management LLC raised its holdings in Pfizer by 192.0% in the fourth quarter. Royal Fund Management LLC now owns 24,713 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 16,249 shares in the last quarter. Sugar Maple Asset Management LLC acquired a new stake in Pfizer in the fourth quarter valued at $43,000. Culbertson A N & Co. Inc. increased its stake in Pfizer by 3.2% during the fourth quarter. Culbertson A N & Co. Inc. now owns 22,485 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 700 shares during the last quarter. Pure Financial Advisors LLC increased its stake in Pfizer by 13.4% during the fourth quarter. Pure Financial Advisors LLC now owns 24,966 shares of the biopharmaceutical company’s stock valued at $662,000 after purchasing an additional 2,945 shares during the last quarter. Finally, Bonness Enterprises Inc. increased its stake in Pfizer by 3.4% during the fourth quarter. Bonness Enterprises Inc. now owns 161,508 shares of the biopharmaceutical company’s stock valued at $4,285,000 after purchasing an additional 5,300 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Price Performance

PFE stock opened at $26.30 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a market capitalization of $149.06 billion, a PE ratio of 35.55, a P/E/G ratio of 0.63 and a beta of 0.64. The firm has a 50-day moving average of $26.08 and a two-hundred day moving average of $27.99.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company earned ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.54%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.